Dr. Bosch acknowledges checkpoints ultimately upregulate CIs when DCVax-Direct is administered, demonstrating the tumor does not wish to go down without a fight, and yet disease stabilization continues. Macrophage upregulation of checkpoint molecules appears to be the primary target for CI intervention. Consequently, it appears he intends to test CI adjuvant therapy subsequent to DCVax-Direct initiation, but otherwise concurrently. I suspect that any trial arm including a CI therapy adjuvant will administer it intratumorally In order to increase safety and efficacy. This may have the added benefit of reducing quantity and thus cost otherwise associated with CI therapies.
(Note: Please delete 35225 and 35226.)
News 
Market Data 
Discover 
AI
